Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL

Braidwell LP raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 550.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,750,092 shares of the company’s stock after acquiring an additional 2,327,205 shares during the quarter. Braidwell LP owned approximately 3.51% of Replimune Group worth $11,523,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Erste Asset Management GmbH increased its position in shares of Replimune Group by 13,597.5% during the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after purchasing an additional 1,618,100 shares in the last quarter. Readystate Asset Management LP raised its stake in Replimune Group by 1,296.2% in the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after purchasing an additional 2,433,292 shares during the last quarter. Saturn V Capital Management LP purchased a new position in Replimune Group in the 2nd quarter valued at $1,198,000. Squarepoint Ops LLC lifted its holdings in Replimune Group by 394.0% in the 2nd quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after purchasing an additional 54,178 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Replimune Group during the 2nd quarter worth $583,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Down 5.8%

Shares of NASDAQ:REPL opened at $7.14 on Friday. Replimune Group, Inc. has a 52-week low of $2.68 and a 52-week high of $13.24. The stock has a market cap of $589.55 million, a P/E ratio of -2.08 and a beta of 0.72. The business has a fifty day moving average of $7.73 and a two-hundred day moving average of $7.67. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.08. On average, research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on REPL shares. Wedbush upped their target price on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Piper Sandler increased their price objective on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.